BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Celgene Corporation 

Corporate Headquarters
86 Morris Avenue
Summit  New Jersey  07901  U.S.A.
Phone: 908-673-9000 Fax: 908-673-9001


SEARCH JOBS

View Clinical Trials from BioPharm Insight

BUILDING FOR SUCCESS
Celgene Corporation is delivering the promise of science to patients and their families facing extraordinary challenges with cancer and inflammatory disease through innovative next generation therapies. Driving profitability are marketed products, which include THALOMID (thalidomide), ALKERAN (melphalan), Focalin™, cellular and tissue therapeutics, as well as the Ritalin family of drugs.

ABOUT CELGENE
Celgene, as a leader in global biotechnology, has built a meaningfully integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based therapies and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.

RECENT PIPELINE HIGHLIGHTS
REVIMID: In February 2003 and April 2003, REVIMID received fast track designation from the FDA for the treatment of multiple myeloma and myelodysplastic syndromes, respectively. REVIMID is currently being tested in two pivotal Phase III FDA SPA trials for the treatment of multiple myeloma and metastatic melanoma. Furthermore, in May, at the International Myelodysplastic Syndromes meeting in Paris, France, REVIMID was the highlight of a study demonstrating medically meaningful erythroid and cytogenic response in MDS patients. That study, initiated by Dr. Alan List of the Moffitt Cancer Center, Tampa Florida, provided the foundation for Celgene to accelerate the potential approval of REVIMID by initiating four Phase II clinical trials; two multicenter Phase II studies in red blood cell transfusion dependent subjects with MDS with or without an associated 5Q minus cytogenetic abnormality and one phase II study in multiple myeloma.

THALOMID: Clinical investigators from leading cancer research centers around the world presented clinical data on THALOMID (thalidomide) in a broad range of hematological malignancies and solid tumor cancers at the Ninth Multiple Myeloma Workshop in Salamanca, Spain and at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, respectively. Several highlighted presentations provided new information on the potential of THALOMID across all stages of multiple myeloma as well as a wide range of solid tumor cancers, including renal cell carcinoma, prostate cancer and malignant melanoma.

ACTIMID™: Our next high-potential orally administered IMiD, is being evaluated in a Phase I/II clinical trial in refractory multiple myeloma and Phase II clinical trial in Prostate cancer. Interim data from an ongoing Phase I/II trial of ACTIMID in 18 relapsed and refractory multiple myeloma patients indicates that ACTIMID has anti-tumor activity in multiple myeloma and has an acceptable toxicity profile.

Key Management:
John W. Jackson - Executive Chairman
Sol J. Barer - Chief Executive Officer
Robert J. Hugin - President and Chief Operating Officer

 Key Statistics


Email:
Ownership:

Web Site: Celgene Corporation
Employees:
Symbol: CELG
 



Industry
Biotechnology






 Company News
Celgene Corporation (CELG) To Announce Second Quarter 2014 Results On July 24, 2014 7/1/2014 12:00:45 PM
Celgene Corporation (CELG) Mourns The Passing Of Board Of Director Member, Rodman L. Drake 6/26/2014 7:47:42 AM
Celgene Corporation (CELG) Stockholders Approve Two-for-One Stock Split 6/19/2014 10:04:57 AM
Celgene Corporation (CELG) Grabs Rights To Agios Pharmaceuticals (AGIO)' Lead Cancer Drug 6/13/2014 6:58:05 AM
Celgene Corporation (CELG) Wagers $25 Million On Nanthealth 6/10/2014 11:00:12 AM
NanoString Technologies Inc. (NSTG), Celgene Corporation (CELG) Strike $45 Million Companion Diagnostic Pact 6/3/2014 5:00:15 PM
Celgene Corporation (CELG) To Present At Investor Conferences In June 5/20/2014 6:59:53 AM
Celgene Corporation (CELG) Prices $2.5 Billion Of Senior Unsecured Notes 5/7/2014 8:10:37 AM
Celgene Corporation (CELG) Prices $2.5 Billion Of Senior Unsecured Notes 5/7/2014 6:45:37 AM
Celgene Corporation (CELG) Announces Offering Of Senior Unsecured Notes 5/6/2014 11:00:07 AM
12345678910...